纳武单抗在异基因造血干细胞移植后复发/难治性ALK阴性间变性大细胞淋巴瘤中诱导持久缓解——病例报告及文献综述
Nivolumab Induces Durable Remission in Relapsed/Refractory ALK-Negative ALCL After Allogeneic Blood Stem Cell Transplantation-A Case Report and Literature Review.
作者信息
Baermann Ben-Niklas, Nachtkamp Kathrin, Jäger Paul, Kessler Paula, Novruzov Emil, Giesel Frederik L, Peters Helena, Seidl Maximilian, Uhlenbruch Mark, Dietrich Sascha, Kobbe Guido
机构信息
Department of Hematology Oncology and Clinical Immunology Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf Düsseldorf Germany.
Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf Düsseldorf Germany.
出版信息
EJHaem. 2025 Jun 4;6(3):e70041. doi: 10.1002/jha2.70041. eCollection 2025 Jun.
BACKGROUND
Relapsed or refractory anaplastic large cell lymphoma (r/r-ALCL) remains an important therapeutic challenge, especially after allogeneic stem cell transplantation (alloHSCT). Due to encouraging results in other lymphoid diseases, PD-1 blockade was investigated in T-cell lymphoma in a small number of patients, but short duration of remission and significant adverse events were observed.
CASE REPORT
Here, we report successful and durable remission induction for more than 2 years with nivolumab for r/r-ALCL even without any evidence of PD-L1 expression.
CONCLUSION
This report and literature review emphasizes the importance of the graft-versus-lymphoma effect and its potential pharmacological stimulators in the field of lymphoma treatment.
背景
复发或难治性间变性大细胞淋巴瘤（r/r-ALCL）仍然是一项重大的治疗挑战，尤其是在异基因干细胞移植（alloHSCT）之后。由于在其他淋巴疾病中取得了令人鼓舞的结果，因此在少数T细胞淋巴瘤患者中对PD-1阻断进行了研究，但观察到缓解期短且有显著不良事件。
病例报告
在此，我们报告了使用纳武单抗治疗r/r-ALCL成功诱导并持续缓解超过2年，甚至没有任何PD-L1表达的证据。
结论
本报告和文献综述强调了移植物抗淋巴瘤效应及其潜在药理学刺激剂在淋巴瘤治疗领域的重要性。
Zotero 插件